7 Pulmonary Fibrosis Headlines You Can’t Miss
In this article, we’re focusing on bringing you non-pharmacological pulmonary fibrosis treatments. Check this list to discover 6 non-pharmacologic pulmonary fibrosis treatments.
This video from the Lung Institute shares some facts on how stem cells can be taken from the patient’s own body and reintroduced to help promote healing and improve lung function. Click to watch the video.
Clinicians managing people with idiopathic pulmonary fibrosis (IPF) are left with few options once the disease seriously progresses, despite pirfenidone treatment. Now a study shows that continuing treatment is the best way to move forward, as it is likely to prevent an even greater decline in lung function and improve life expectancy.
FibroGen, Inc., recently disclosed potentially groundbreaking results from a Phase 2 clinical trial evaluating the efficacy of the company’s investigational drug FG-3019 in the treatment of idiopathic pulmonary fibrosis (IPF). Data indicated the monoclonal antibody agent was able to reduce lung fibrosis in a portion of the IPF patients enrolled, to improve overall lung function.
C-type natriuretic peptide (CNP) is already known to protect against fibrosis in heart tissue. Researchers from the National Cerebral and Cardiovascular Center, Japan, have now shown that CNP can also improve lung fibrosis in a mouse model by preventing the formation of myofibroblasts.
A new study shed light on a growth factor which might protect lung cells in pulmonary fibrosis. Researchers from Shanghai, China, found that fibroblast growth factor-10 (FGF-10) prevented damage in rat lung cells, and may also direct the development of lung stem cells.
The study, “Fibroblast Growth Factor-10 (FGF-10) Mobilizes Lung-resident Mesenchymal Stem Cells and Protects Against Acute Lung Injury,“ appeared on Feb. 12, 2016, in the journal Scientific Reports.
In this article, check out our list of seven possible risk factors for pulmonary fibrosis.